REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 12th, 2014 • CB Pharma Acquisition Corp. • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of the _________, 2014, by and among CB Pharma Acquisition Corp., a Cayman Islands company (the “Company”), and the undersigned parties listed under Investor on the signature page hereto (each, an “Investor” and collectively, the “Investors”).
RIGHTS AGREEMENTRights Agreement • November 12th, 2014 • CB Pharma Acquisition Corp. • Blank checks • New York
Agreement made as of _______, 2014 between CB Pharma Acquisition Corp., a Cayman Islands Company, with offices at 24 New England Executive Park, Suite 105, Burlington, Massachusetts 01803 (“Company”), and Continental Stock Transfer & Trust Company, a New York corporation, with offices at 17 Battery Place, New York, New York 10004 (“Right Agent”).
WARRANT AGREEMENTWarrant Agreement • November 12th, 2014 • CB Pharma Acquisition Corp. • Blank checks • New York
Agreement made as of _______, 2014 between CB Pharma Acquisition Corp., a Cayman Islands Company, with offices at 24 New England Executive Park, Suite 105, Burlington, Massachusetts 01803 (“Company”), and Continental Stock Transfer & Trust Company, a New York corporation, with offices at 17 Battery Place, New York, New York 10004 (“Warrant Agent”).
CB Pharma Acquisition Corp. Burlington, Massachusetts 01803 EarlyBirdCapital, Inc. New York, New York 10016Underwriting Agreement • November 12th, 2014 • CB Pharma Acquisition Corp. • Blank checks
This letter is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between CB Pharma Acquisition Corp., a Cayman Islands Company (the “Company”), and EarlyBirdCapital, Inc., as Representative (the “Representative”) of the several Underwriters named in Schedule I thereto (the “Underwriters”), relating to an underwritten initial public offering (the “IPO”) of the Company’s units (the “Units”), each comprised of one ordinary share of the Company, par value $0.0001 per share (the “Ordinary Shares”), one right (“Right”) to receive one-tenth of one Ordinary Share upon consummation of the Company’s initial Business Combination, and one warrant, each warrant exercisable for one half of one Ordinary Share (“Warrant”) upon consummation of the Company’s initial Business Combination. Certain capitalized terms used herein are defined in paragraph 15 hereof.
SHARE ESCROW AGREEMENTShare Escrow Agreement • November 12th, 2014 • CB Pharma Acquisition Corp. • Blank checks • New York
SHARE ESCROW AGREEMENT, dated as of ___________, 2014 (“Agreement”), by and among CB PHARMA ACQUISITION CORP., a Cayman Islands Company (“Company”), Coronado Biosciences, Inc., ADAM J. CHILL, ARTHUR A. KORNBLUTH and NEIL HERSKOWITZ (collectively “Initial Shareholders”) and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, a New York corporation (“Escrow Agent”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • November 12th, 2014 • CB Pharma Acquisition Corp. • Blank checks • New York
This Agreement is made as of _________, 2014 by and between CB Pharma Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company (“Trustee”).
CB Pharma Acquisition Corp.CB Pharma Acquisition Corp. • November 12th, 2014 • Blank checks
This letter will confirm our agreement that, commencing on the effective date (the “Effective Date”) of the registration statement (the “Registration Statement”) for the initial public offering (the “IPO”) of the securities of CB Pharma Acquisition Corp. (the “Company”) and continuing until the earlier of (i) the consummation by the Company of an initial business combination or (ii) the Company’s liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”), Coronado Biosciences, Inc. shall make available to the Company certain office space and administrative and support services as may be required by the Company from time to time, situated at 24 New England Executive Park, Suite 105, Burlington, Massachusetts 01803 (or any successor location). In exchange therefore, the Company shall pay Coronado Biosciences, Inc. the sum of $10,000 per month on the Effective Date and continuing monthly thereafter until the
